4 active not recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 4 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow wAMD: new trials by email Literature Review of wAMD trials Research Report on wAMD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 EYP-1901, Aflibercept (2.0 mg) - Wet Age Related Macular Degeneration, wAMD | Phase 3 | Active not recruiting | EyePoint Pharmaceuticals, Inc. | 400 | 2024-11-27 | 2026-09-03 |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 EYP-1901, Aflibercept (2.0 mg) - Wet Age Related Macular Degeneration, wAMD | Phase 3 | Active not recruiting | EyePoint Pharmaceuticals, Inc. | 400 | 2024-10-22 | 2026-09-03 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
Choroidal Neovascularization (2) · Eye Diseases (2) · Macular Degeneration (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Wet Macular Degeneration (2)
Choroid Diseases (2) · Eye Diseases, Hereditary (2) · Metaplasia (2) · Neovascularization, Pathologic (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Uveal Diseases (2)
aflibercept (3) · Ranibizumab (1)
AbbVie (2) · EyePoint Pharmaceuticals, Inc. (2)
United States (4) · Germany (2) · Hungary (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Puerto Rico (1) · Slovakia (1)